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    Bacteriophages are viruses that infect bacteria, and are distinct from animal and plant viruses that could 
have either lytic or lysogenic cycle. Lytic phages known as candidates for phage therapy, since they 
rapidly replicate into their host and lyse them. Theoretically, phages have more than a few benefits over 
routine antibiotics. They are extremely specific for their targeted hosts and also are safe for human, 
because they have no activity against eukaryotic cells. Over this time, phages were used to treat various 
infections. Although, phages have a number of advantages over antibiotics, their industrial production as a 
commercial product ceased in most of the western European countries after the introduction of antibiotics.  
These days, by increasing of antibiotics resistance and inefficiency of antibiotics against bacterial 
biofilms,  there is renewed global interest in phage applications as potentially powerful antibacterial 
agents. Different published paper through the world indicates bacteriophages could be recruited as 
suitable agent for therapeutic purposes in medicine and food industry. Therefore, here we tried to review 
most of these ideas about phage application as a rapid review.  
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INTRODUCTION
     Bacteriophages are an order of viruses that 
are able to infect bacteria, resulting usually in 
propagative lysis (lytic cycle) or lysogenization 
(lysogenic cycle) of the infected cell. Lytic 
phages may be candidates for phage therapy, 
because they replicate fast within their hosts and 
lyse them. Based on the species of phage and 
host, phages could be produced between 50 and 
250 progeny per infective life cycle (Fig-1). 
Each daughter infects a host and produce 40,000 
progeny at the end of the second cycle. This will 
result in 8 million progeny at the end of the 
third cycle and 1.6 billion at the end of the 
fourth cycle [1]. Theoretically, phages have 
more than a few benefits over routine 
antibiotics. They are strongly specific for their 
targeted bacteria and also are safe for human, 
since they did not show any activity against 
eukaryotic cells. Bacteriophage therapy as an 
emerging methods to combat with bacterial 
infections is presented [2]. Phage recruiting as 
a therapeutic agent was initiated in 1919, short 
times after its discovery, to the treatment of 
dysentery and it is continued until the 1940s. 
Over this time, phages were used to treat 
various infections. Although, phages have a lot 
of advantages against antibiotics, their 
industrial production as a commercial product 
ceased in most of the western European 
countries [3, 4]. These days, by raising of 
antibiotics resistance and inefficiency of 
antibiotics against bacterial biofilms, there is 
renewed global attention in phage applications 
as a potentially powerful antibacterial agents. 
There are various published paper throughout 
the world that indicate bacteriophages could be 
recruited to phage therapy, both in humans and 
animals, and also in food industry [5- 7] . 
 






Figure 1.  Lytic Cycle. 1) A phage recognizes a specific receptor on host and attaches to its host via that receptor, and 2) injects its 
DNA.  3)  Phage by disrupting the host replication induce the bacterium killing, 4) taking over the bacterial DNA replication and 
protein synthesis machinery to make its parts. 5) This process ends with the assembly of new phage, and 6) the lysis of the host cell 
wall to release a hundred new copies of phage. (This image is designed by Our teams in MahanGenePajoh Co.) 
 
Broad Host Range bacteriophage: 
    Bacteriophages like other viruses as obligate 
intracellular parasites must enter an appropriate 
host to reproduce. Their infection are initiated 
when the virions interact with receptors on the 
surface of host cell. Most of bacteriophages are 
known to be  extremely specific for their hosts 
(because of specific receptors) [8]. In contrast, it 
is clear that some bacteriophages are called 
broad host range could infect a range of 
bacterial species (Fig-2). P1 and Mu are 
presented as broad host range bacteriophages. 
P1 is able to produce plaque on several enteric 
species culture in addition to E.coli, while 
bacteriophage Mu produces progeny virions on 
different bacterial species because of the the 
variation of invertible viral G segment region 
orientation [9]. Based on the origin of virus 
particles that make up a large amount of the 
dissolved organic carbon in all ecosystems as 
well as marine ecosystems, the prevalence of 
broad-host-range phages would be different [10, 
11]. 
Bacteriophage and biofilm: 
    Bacteria attach to both surfaces: biotic and 
abiotic, and form densely and packed bacterial 
cells embedded in an extracellular 
polysaccharide matrix known as a biofilm [12]. 
One of the most important specificity of these 
attached cells is up to 1000 times higher 
resistance to antimicrobial agents, primarily as 
the result of slow growth and presence of 
impermeable exopolysaccharides (EPS) on 
bacterial surface [13]. 
 
 
Figure 2. Isolated phage against P.aeruginosa (ATCC: 
PAO) from sewage, which effect against E.coli, P.putida 
and  A. baumannii, Ilam University of Medical Sciences. 
R.Azizian, Clinical Microbiology Research Center, Ilam 
University of Medical Sciences  
 




Phages have been examined to a lesser extent as 
a potential agents to control biofilm [14-17]. 
Phage application has ability to degrade EPS by 
enzymes attached to their base plate- 
polysaccharide depolymerases and lyases, 
important for penetration into a host cell [16]. 
Phage enzymes has potency to eliminate or 
inhibit biofilm formation. Different Multiplicity 
of Infection (MOI: the ratio of infectious phage 
to infection host) is needed to bacterial growth 
and probably phage enzymatic activity inhibit 
biofilm forming. While primary receptors are 
located on outer membrane, EPS acts as a 
secondary receptor for some of phages [18]. 
 Even if a phage cannot attach to primary 
receptors and infect cells, it can degrade EPS 
and inhibit biofilm formation [19]. Although 
phages showed considerable effect on growth 
inhibition and biofilm formation, their effect on 
already formed biofilm was very low. It is not 
unexpected, as phages are usually highly 
specific for their receptors and slightly different 
receptors structure on bacterial surface may 
result in resistance to phage infection [20]. 
McLaughlin and colleagues experiments 
illustrate this event by an emergence of mutant 
species that show resistant to phages (21). 
Mutants usually spontaneously appear during 
overnight incubation of bacteria and phages, 
and it could be explain this phenomenon [22]. 
 
Bacteriophage and Quorum-sensing: 
    Quorum-sensing known as a mean pathway 
of regulating the interactions between bacteria 
and its responses to environmental signals and 
density of population, is presumed to be 
recruited to regulate antiviral defense strategies. 
 The bacterium related evolution of phage is 
characterized by altering selection and thus 
generates bacteria that are more resistant to 
current phages than to past [23, 24]. 
Phage defense mechanism that regulated by 
quorum-sensing signaling pathway could play a 
main role on the phage evolution in their natural 
hosts and environments. To explain phage 
coexistence with their hosts, different 
mechanisms are presumed that would generate a 
minority group of host cells that are protected 
from infection, this group by stochastic 
fluctuations in receptor expression, decrease 
lysis in stationary phase  [25, 26].  
E. coli has evolved the ability to increase the 
subpopulation of phage-tolerant receptor-free 
cells at times by subjecting genes encoding 
phage receptors (LamB and flagella) to quorum- 
sensing control [27]. Quorum-sensing-mediated 
down-regulation of phage susceptibility may 
well turn out to be an important factor in 
understanding phage-host coexistence. Albeit, 
quorum- sensing has been found to up-regulate 
the generation of all of these minority groups 
[28, 29] 
 
Bacteriophage in industry 
Poultry: 
    Phages were recruited as a spray and 
intramuscular injection, to cure Escherichia coli 
infection in chicken [30]. These products 
experiments shown, when the equal number of 
phage and bacteria were utilized, no morbidity 
was observed at all, but 100-fold lower phage 
titration also conferred significant protection, 
demonstrate the multiplication of the phage in 
in-vivo. Phage therapy was effective in most of 
studies, even at the onset of clinical symptoms 
[2, 31, 32]. 
 
Meat (Calves): 
    Phage application in calves prevent diarrhea, 
but it does not efficiency at the initiation of 
symptoms, although it strongly prevent death 
[33]. Phage titration in feces is high but it is not 
detectable in blood and spleen. Although, there 
is phage-resistant cells in most of the calves, 
their titration remained low. Mutant cells 
indicate less competitive effect than their 
parents through re-inoculation into new claves 
[32]. 
In other study, recruited low dose of phage (10
5
 
p.f.u.) investigated at the onset of diarrhea and 
calves were sacrificed in a time series. After 40 
hours when bacteria were not detectable, phages 
disappeared, but there appeared a range of 
bacteria which shown resistance to 
bacteriophage. Remained bacteria had lost 
major potency to produce infection [33]. 
 




Phages have this potency to survive at room 
temperature almost 100 days, resistance to 
phenolic disinfection [34, 35], confirmed that 
intramuscular injection in  calves postponed the 
presence of the bacterium in the faeces and 
blood of animal. This sort of phage application 
improve the life length of the animals [34, 35]. 
 
Commercial Products: 
    Phages exploited in the USA as commercial 
products. Various products were designed by 
recruiting proteolytic enzymes of lytic phages in 
USA. For examples a bandage designed for 
treating a bacterial infection of skin involves 
groups of bacteria such as; Staphylococcus, 
Pseudomonas, Streptococcus. This lytic enzyme 
is specific and has the ability to digest a cell 
wall of the bacteria and is coded by the same 
bacteriophage capable of digesting infected 
bacteria. The enzyme produced is mixed with a  
carrier, (Patent’s No: 6432444; 
http://www.patentstorm.us/patents/6432444.htm
l) [36] .  
 In addition, a chewing gum was produced that 
its composition included of mixing an effective 
amount of proteolytic enzyme produced by 
group C streptococcal bacteria infected with a 
C1 bacteriophage and a carrier for delivering 
these enzyme via mouth, throat, or nasal 





Phage-Antibiotic Synergy (PAS): 
    André M. Comeau study indicates 
surprisingly, the phage plaques zone increase 
with some of β-lactam antibiotics disks where 
there was a sub-lethal concentration of them. 
This effect was observed for aztreonam, 
monobactam, cefixime, and cephalosporin 
disks, but not for tetracycline and gentamicin 
[38]. Hence, a sub-lethal dosage of β-lactam 
antibiotics stimulate phage propagation within 
host. This synergistic effect called the Phage 
Antibiotic Synergy (PAS). Recently, it has been 
indicated that the inactivation of Penicillin 
Binding Protein III synthesis gene (ftsI) by β-
lactam antibiotics also induces the expression of 
the SOS response system via a two-component 
signaling pathway. SOS response to β-lactam 
antibiotics in bacteria leads in filamentation that 
allows the host to decreas the lethal effects of 
the antibiotics [39].  
Thereby, it seems that the phenotype of 
filamentation plays an important role in the PAS 
effect, possibly through various pathways. 
Filamentation cell altering clearly make phage 
assembly faster, maybe by inducing alteration in 
the peptidoglycan layer that this possibly results 
a more sensitivity to the lysis action of phage 
(e.g. lysozymes, holins) [38]. 
  
Human phage therapy Efforts: 
   550 cases of bacterial infections such as 
empyemas, peritonitis, osteomyelitis, and etc in 
humans were investigated by a group led by  
Prof. S. Slopek (Institute of Immunology and 
Experimental Therapy, branch of Polish 
Academy of Sciences) in the mid-1980s [40]. 
Most of these cases were chronic and resistant to 
routine antibiotics. Pathogenic bacteria were 
involved Staphylococcus aureus, Pseudomonas 
aeruginosa, Klebsiella pneumoniae and E. coli 
[40]. Recruited phages by S. Slopek’s group 
have cured approximately 90% of the cases [40]. 
Cessation of suppuration and, where applicable, 
complete closure of wounds or fistulae presumed 
as criteria of the cure. To prevent biohazard of 
remained bacteria debris, it is preferred to not use 
oral administration. Patients were received anti-
acids and gelatin in order to protect the phages 
from gastric acid destruction potential [40]. Prof. 
S. S´ lopek and his colleagues have been rigorous 
in matching the phages to the bacterial strain 
infecting the given patients. They cultured the 
bacteria during the course of treatment, so that 
the occurrence of a mutant resisting the phage 
can be countered by switching to a different 
phage strain. This group also had panels of 
multivalent phages available, to use in fulminate 
infection such as  septicemia. The statistics of 
achievement cure of human cases by this group 
were approximately 1,300 ones. Overlay, the rate 
of cure across the pathogens and infection sites 
was nearby 86%  [40]. 
 







Table.1. Chronologically table of selected studies 
Row Researcher Year Title Results 
1 Jingmin Gu 2011 A Method for Generation 
Phage Cocktail with Great 
Therapeutic Potential 
Phage cocktail as a more effective agent in bacterial mutation 
frequency reduction than monophage suggesting that produced 
cocktail by SBS method has strong therapeutic potency to treat 







Application of a 
bacteriophage cocktail to 
reduce S.typhimurium 
U288 contamination on pig 
skin 
Phage cocktail application produced significant reductions of S. 
typhimurium U288 on experimentally-contaminated pig skin; 
however this appears to be linked to an MOI in excess of the 








processing of pathogenic 
Escherichia coli and its 
biofilms 
Phage bio-processing of vegetables, egg, and meat was highly 
successful in eliminating completely E. coli. Moreover, using 
designed phage master mix was shown to cover all of the tested 
E. coli bacteria without show signs of the development of 
bacterial resistance. On the other hand, phage bio-processing 




2011 Novel Virulent and Broad-
Host-Range Erwinia 
amylovora Bacteriophages 
Reveal a High Degree of 
Mosaicism and a 
Relationship to 
Enterobacteriaceae Phages 
 L1, M7, S6, and Y2 were introduced as bio-control phages of 
fire blight. All of them are broad host ranges. Analysis of 
sequencing details provided information to avoid undesired 
transfer of host genetic material and facilitated complementary 







Characteristics of a phage 
effective for colibacillosis 
control in poultry 
Phage ØEC1, is be able to reduce infection b y E. coli 
O78:K80,14. It shown an optimum MOI of 0.1 – 1. This Phage 
has characteristics can serve as a guideline for selection of 
effective candidates for phage therapy, in colibacillosis control 








A Genetic Approach to the 
Development of New 
Therapeutic Phages to 
Fight Pseudomonas 
aeruginosa in Wound 
Infections. 
Live phages utilizing as a therapeutic agent is valid only in 
direct contact with the virus and bacteria. Although, the direct 
usage of highly purified phage in the blood could be very risky 
[41]. 






AHL signaling in quorum sensing response leads to 
downregulation of the number of LamB receptors, which causes 
increase survival bacteria. Also, this mechanism protect bacteria 
against broad-host-range phage χ [27]. 
 
Limitations of  Human Bacteriophage 
Therapy: 
Utilizing of live phages in order to phage 
therapy is valid only in cases that provide direct 
contact between the virus and bacterial host 
[41]. However, exploitation of highly purified 
phage in human fluids like blood ( in septicemia 
case) is very risky [42]. Also, there is an 
unobvious debate on oral administration of 
phages because it is presumed on some of 
literatures that phages might penetrate into the 
blood, and then arrive to the urine [43]. But, the 
phage utilizing for wound, urogenital, intestinal, 
eye infections and infections of the ear, nose 
and throat are suitable. Though, a lot of efforts 
done in animal models, phages are not 
applicable to achieve Cystic fibrosis cure, due to 
phages of P. aeruginosa are in contact with 
different phages and there is not any specific 
direct contact [44].  
A particular mixture of phages has not sufficient 
ability to offer long-term efficiency as 
 




therapeutic agent. Commercial cocktails of 
phages which manufactured by companies were 
included with  broadest spectrum of lytic 
activity for their hosts. Despite of the spectrum 
of lytic activity of phage cocktail, survived 
bacteria might reveal resistance to cocktail after 
a short time of cure initiation. Consequently, 
single mutation in Gram-negative bacteria like 
P.aeruginosa, leading to resistance to 
attachment, and might inhibit the phage growth 
within host and lytic activity  [43]. 
 
CONCLUSION 
    Based on antibiotics resistant infections 
emergence throughout the world, seeking for 
appropriate antimicrobial agents to deal with 
this issue has become a critical topic in health 
world. Previous of the antibiotics discovery and 
widespread usage of them, it was presumed that 
bacteriophages could be exploited to combat 
with bacterial infections. 
 Although there is not global agreement to use 
bacteriophages for therapeutic purposes 
specially in human, some of countries believe it 
could be useful. Bacteriophages are introduced 
as high specific antibacterial agents which lysis 
targeted bacteria,  and rapidly modify to combat 
with the appearance of recently bacterial 
infections. 
A lot of published studies suggest that phages as 
therapeutic agents might be effective in chosen 
clinical settings, many of them believe  there is 
not any globally approved standards for clinical 
trials and  there is still remained many 
unanswered questions that must be response 
before widely usage of lytic phages (Table-1)  
[46]. For the future phage therapy, most of 
aspects must be determined by attitude of health 
authorities that allow to use of phages.  
Currently, there is a globally conflict  about 
phage usage, in the West, the US Food and 
Drug Administration, prefer to use a single well 
known phage, while in the East, phage therapy 
lay in phage cocktails. Even individualized 
treatments done for each patient by using 
specific phages which isolated against the agent 
of infection in surgical settings [45]. Also, 
Intesti-phage that was a mixture of a group of 
phages against E. coli and other Enterobacteria 
[47]  was made in large quantity 80 % in the 
1980s. This product were used widely by Soviet 
army, as prophylactic and without any particular 
pre-testing in the individual patients [48].  
In other hand, phage purification, stabilization 
and sterilization are time spending and 
expensive process that need complicated and 
equipped laboratories base of standardization of 
Good Manufacturing Practices (GMP) protocols 
recruiting.  
According to large of unanswered questions in 
phage therapy scope, and success of phage 
recruiting in industry, it is obvious that phage 
could be suitable antimicrobial agent in 
industries. But, to achieve a global agreement 
about phage therapy, there is need to establish 
an international institute that prepare an 
standard to provide clinical approves.  Also, 
based on our rapid review, bacteria improve 
their manner when they have interaction with 
phage and shown resistance to phage. 
According to successful experiments about 
proteolytic enzymes of phage in commercial 
products such as toothpaste, chewing gum, and 
ointment for dermatological treating. It is 
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